Clinical trialNCT04672005UnknownPhase 2Interventional

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

SponsorLyudmyla BerimEnrollment30Metastatic Pancreatic Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The main objective of the clinical trial is to determine if modified FOLFIRINOX (mFFX) alternated with biweekly Gemcitabine plus Nab-Paclitaxel (mGnabP) administered as a combined, front-line therapy will result in longer time to treatment failure (TTF) compared to the current standard of care with mFFX alone in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Lyudmyla Berim, MD
Rutgers Cancer Institute of New Jersey
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Rwjbarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton, New Jersey, United States
Rwjbarnabas Health - Jersey City Medical Center, Jersey City
Jersey City, New Jersey, United States
Rwjbarnabas Health - Saint Barnabas Medical Center, Livingston
Livingston, New Jersey, United States
Monmouth Medical Center
Long Branch, New Jersey, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Rwjbarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States
Rwjbarnabas Health - Robert Wood Johnson University Hospital, Somerset
Somerset, New Jersey, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Folfirinox alternating with Gemcitabine-nab-Paclitaxel

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Jan 2021
Primary completion: 30 Sept 2024
Completion: 1 Jun 2025
Last update posted: 16 May 2024
Registered enrollment: 30
Registry id: NCT04672005

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.